Reviewing the Role of Advanced Glycation Endproducts in Aging and Age-Related Disease
Glycation arises from the interaction of sugars with proteins, decorating proteins with additional structures that alter their function. Advanced glycation endproducts (AGEs) are a broad class of glycated proteins. The presence of AGEs is a form of stress on cells and systems in the body; some forms drive chronic inflammation through interaction with the receptor for AGEs (RAGE), while other forms alter the structural properties of the extracellular matrix by cross-linking collagen and other molecules to restrict their motion. Relatively little work has taken place on ways to address the problem of excessive AGEs in aging and age-related disease, unfortunately. Compared to more popular topics in the life sciences, the study of AGEs, and particularly their interactions with the extracellular matrix, remains underfunded and gives rise to little in the way of efforts to produce therapies to tackle this aspect of aging.
Biological molecules seldom act alone. Within the crowded environment of a cell, proteins, lipids, and nucleic acids are constantly surrounded by sugars and metabolites that test their stability and shape. Among these interactions, glycation stands out as a subtle yet far-reaching reaction, linking the routine chemistry of metabolism to the gradual story of molecular aging. Often described as the Maillard reaction, glycation is a spontaneous nonenzymatic process in which simple sugars or their reactive derivatives attach covalently to amino acid residues such as lysine, arginine, and cysteine. The resulting adducts evolve into Amadori compounds and eventually into advanced glycation end products (AGEs), which alter protein conformation, solubility, and biological activity.
In living systems, glycation proceeds slowly but accelerates with age, becoming a hallmark of molecular aging. Beyond structural damage, AGEs act as signaling molecules by binding to the receptor for advanced glycation end products (RAGE). This interaction triggers oxidative stress, inflammation, and tissue remodeling that contribute to chronic disease. Clinically, glycation serves as both a biomarker and a therapeutic target. Measurements such as glycated hemoglobin and glycated albumin provide indicators of metabolic control, while pharmacological and nutritional strategies aim to limit AGE formation, disrupt crosslinks, or block receptor-mediated signaling
This review synthesizes the molecular pathways of AGE formation, their structural diversity, and the biological factors influencing glycation kinetics. Advances in analytical detection methods - including fluorescence spectroscopy, LC-MS/MS, and immunochemical approaches - are highlighted for their role in monitoring AGE accumulation. Particular attention is given to the contribution of glycation to diabetes, cardiovascular disease, neurodegeneration, and cancer, alongside emerging therapeutic strategies to limit AGE formation or block AGE-RAGE signaling. Glycation thus represents a central mechanism in human disease pathogenesis and an emerging therapeutic frontier.